Clene prices $7M stock offering to fund NDA filing and Phase 3 trial for lead drug

Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read

Key Changes

• high

  Clene is selling 1 million shares at $7.00 per share through Canaccord Genuity, raising approximately $6.4 million net after fees. Proceeds will fund the NDA filing for CNM-Au8, Phase 3 clinical trials, manufacturing expansion, and early-stage R&D.

  Item 1.01 verify on EDGAR →
• high

  The offering dilutes existing shareholders by approximately 1 million shares. Underwriting fees are 6.5% of gross proceeds plus $140,000 in other expenses, totaling roughly in transaction costs.

  Item 1.01 verify on EDGAR →
• medium

  Company insiders, officers, and directors agreed to a 60-day lock-up preventing them from selling shares without underwriter consent. This restriction helps stabilize the stock price post-offering but expires in early July 2026.

  Item 1.01 verify on EDGAR →